

UNIVERSITY OF BIRMINGHAM

Research at Birmingham

Predictive Biomarkers for Endocrine Therapy

Roseweir, Antonia K; Bennett, Lindsay; Dickson, Ashley; Cheng, Kelvin; Quintayo, Mary-Anne; Bayani, Jane; McMillan, Donald C; Horgan, Paul G; van de Velde, Cornelis J H; Seynaeve, Caroline; Hasenburger, Annette; Kieback, Dirk G; Markopoulos, Christos; Dirix, Luc Y; Rea, Daniel; Mallon, Elizabeth A; Bartlett, John M S; Edwards, Joanne

DOI:

[10.1093/jnci/djx255](https://doi.org/10.1093/jnci/djx255)

License:

Other (please specify with Rights Statement)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Roseweir, AK, Bennett, L, Dickson, A, Cheng, K, Quintayo, M-A, Bayani, J, McMillan, DC, Horgan, PG, van de Velde, CJH, Seynaeve, C, Hasenburger, A, Kieback, DG, Markopoulos, C, Dirix, LY, Rea, D, Mallon, EA, Bartlett, JMS & Edwards, J 2018, 'Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial' *Journal of the National Cancer Institute*, vol. 110, no. 6, pp. 616-627. <https://doi.org/10.1093/jnci/djx255>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 28/06/2018

This is a pre-copyedited, author-produced version of an article accepted for publication in JNCI: Journal of the National Cancer Institute following peer review. The version of record: Antonia K Roseweir, Lindsay Bennett, Ashley Dickson, Kelvin Cheng, Mary-Anne Quintayo, Jane Bayani, Donald C McMillan, Paul G Horgan, Cornelis J H van de Velde, Caroline Seynaeve, Annette Hasenburger, Dirk G Kieback, Christos Markopoulos, Luc Y Dirix, Daniel W Rea, Elizabeth A Mallon, John M S Bartlett, Joanne Edwards; Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial, JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, 1 June 2018, Pages 616–627 is available online at: <https://doi.org/10.1093/jnci/djx255>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

SUPPLEMENTARY MATERIALS

SUPPLEMENTARY METHODS

Patients and study design

The TEAM trial inclusion and exclusion criteria differed slightly by participating country. Eligible patients were postmenopausal women with HRec-positive breast cancer (defined locally), with histologically or cytologically confirmed T1-3 N0-2 M0 adenocarcinoma and adequate local therapy (surgical resection +/- radiotherapy) and/or chemotherapy. The United Kingdom/Ireland (1053/1275; 82.5%), the Netherlands (2710/2753; 98.4%), Belgium (113/414; 27.3%), Germany (670/1471; 45.5%), and Greece (85/207; 41.1%) provided eligible tumour samples from surgical resections for tissue microarray (TMA; n=4631) construction with linked clinicopathological data. This study hypothesised that low expression of our biomarkers would predict response to exemestane alone.

Procedures

Antigen retrieval for IKK α and p44/42 MAPK^{202/204} used citrate buffer pH6 at 96°C, and for ER¹¹⁸, ER¹⁶⁷, p65⁵³⁶, Raf-1³³⁸, and N-Ras used TE buffer pH8 at 96°C. 2% normal donkey serum (ER¹¹⁸/ER¹⁶⁷/IKK α /p65⁵³⁶/N-Ras/Raf-1³³⁸) or 10% Casein (p44/42 MAPK^{202/204}) was the blocking solution. TMA sections were incubated at 37°C with primary ER¹¹⁸ (1:500, Cell Signaling Ltd, #2511), ER¹⁶⁷ (1:200, Cell Signaling Ltd, #5587), IKK α (1:800, Geneway, #GTW662250), p65⁵³⁶ (1:50, Abcam, #ab28856), Raf-1³³⁸ (1:300, Millipore, #05-538), and p44/42 MAPK^{202/204} (1:600, Cell Signaling Ltd, #4376) or at 42°C with primary N-Ras (1:30, Santa Cruz, #SC-51). HRP-multispecies secondary antibody

(Roche) followed by DAB substrate for color development. Slides were counterstained with hematoxylin.

Stained TMA sections were scanned using a Hamamatsu NanoZoomer at x20 magnification and visualized on Slidepath Digital Image Hub (Leica Biosystems). The weighted histoscore is calculated as follows: 0x% not stained + 1x% weakly stained + 2x% moderately stained + 3x% strongly stained and gives a range from 0 to 300.

Supplementary Table 1. Biomarker associations with common clinicopathological factors

Clinicopathological factors	ER ¹⁶⁷ (n=4133)			IKK alpha (n=3024)			Raf-1 ³³⁸ (n=4030)			p44/42 MAPK ^{202/204} (n=4055)		
	Negative (%) (n=1150)	Positive (%) (n=2983)	p value*	Negative (%) (n=1579)	Positive (%) (n=1445)	p value*	Negative (%) (n=2797)	Positive (%) (n=1233)	p value*	Negative (%) (n=2249)	Positive (%) (n=1806)	p value*
Age			0.27			0.75			0.15			0.001
<50	28 (2.4)	76 (2.5)		39 (2.5)	42 (2.9)		60 (2.1)	47 (3.8)		48 (2.1)	62 (3.4)	
50-59	337 (29.3)	901 (30.2)		465 (29.4)	420 (29.1)		866 (31.0)	335 (27.2)		659 (29.3)	546 (30.2)	
60-69	428 (37.2)	1142 (38.2)		604 (38.3)	559 (38.7)		1016 (36.3)	530 (43.0)		833 (37.0)	723 (40.0)	
>70	357 (31.1)	864 (29.1)		471 (29.8)	424 (29.3)		855 (30.6)	321 (26.0)		709 (31.6)	475 (26.4)	
Grade			0.001			0.02			<0.001			<0.001
1	126 (11.0)	363 (12.1)		178 (11.3)	172 (11.9)		406 (14.5)	64 (5.2)		258 (11.5)	212 (11.7)	
2	552 (48.0)	1554 (52.1)		792 (50.2)	752 (52.0)		1267 (45.3)	780 (63.3)		1055 (46.9)	1013 (56.1)	
3-4	412 (35.8)	879 (29.4)		529 (33.5)	430 (29.8)		940 (33.6)	297 (24.1)		766 (34.1)	484 (26.8)	
unknown	60 (5.2)	187 (6.4)		80 (5.0)	91 (6.3)		184 (6.6)	92 (7.4)		170 (7.5)	97 (5.4)	
Nodal Status			0.55			<0.001			<0.001			<0.001
absent	298 (25.9)	746 (25.0)		338 (21.4)	445 (30.7)		351 (12.5)	625 (50.7)		449 (20.0)	537 (29.7)	
present	852 (74.1)	2237 (75.0)		1241 (78.6)	1000 (69.3)		2446 (87.5)	608 (49.3)		1800 (80.0)	1269 (70.3)	
Size			0.04			0.06			<0.001			<0.001
<20mm	531 (46.2)	1463 (49.0)		765 (48.4)	716 (49.6)		1265 (45.3)	670 (54.3)		971 (43.2)	972 (53.8)	
>20mm	600 (52.2)	1428 (47.9)		799 (50.6)	651 (45.1)		1449 (51.8)	471 (38.2)		1203 (53.5)	783 (43.4)	
unknown	19 (1.6)	92 (3.1)		15 (1.0)	78 (5.3)		83 (2.9)	92 (7.5)		75 (3.3)	51 (2.8)	
PR status			0.13			0.02			<0.001			0.23
absent	227 (19.7)	548 (18.4)		335 (21.2)	259 (17.9)		610 (21.8)	183 (14.7)		454 (20.2)	342 (18.9)	
present	757 (65.8)	2041 (68.4)		1118 (70.8)	1006 (69.6)		2010 (71.9)	824 (66.7)		1563 (69.5)	1289 (71.4)	
not performed	116 (14.5)	394 (13.2)		126 (8.0)	180 (12.5)		177 (6.3)	229 (18.6)		232 (10.3)	175 (9.7)	
HER2 status			0.05			<0.001			<0.001			<0.001
absent	406 (35.3)	1218 (40.8)		630 (39.9)	675 (46.7)		933 (33.4)	723 (58.6)		729 (32.4)	952 (52.7)	
present	454 (39.5)	1167 (39.1)		759 (48.1)	423 (29.3)		1653 (59.1)	76 (6.2)		1096 (48.7)	632 (35.0)	
not performed	290 (25.2)	598 (20.1)		210 (12.0)	347 (24.0)		211 (7.5)	434 (35.2)		424 (18.9)	222 (12.3)	
Ki67 status			0.99			0.008			0.004			0.52
low (<15)	607 (52.8)	1602 (53.7)		898 (56.9)	839 (58.1)		1434 (51.3)	635 (51.5)		1176 (52.3)	907 (50.2)	
high (>15)	274 (23.8)	722 (24.2)		374 (23.7)	409 (28.3)		601 (21.5)	337 (27.3)		521 (23.2)	423 (23.4)	
unknown	269 (23.4)	659 (22.1)		307 (19.4)	197 (13.6)		762 (27.2)	261 (21.2)		552 (24.5)	476 (26.4)	
Treatment			0.34			0.44			0.18			0.05
Exemestane	594 (51.6)	1491 (50.0)		791 (50.1)	744 (51.4)		1390 (49.7)	641 (52.0)		1103 (49.0)	942 (52.2)	
Tamoxifen followed by exemestane	556 (48.4)	1492 (50.0)		788 (49.9)	701 (48.6)		1407 (50.3)	592 (48.0)		1146 (51.0)	864 (47.8)	
Lymphovascular Invasion			0.34			0.54			0.95			<0.001
no	978 (85.0)	2509 (84.1)		1327 (84.0)	1209 (83.7)		2345 (83.8)	1043 (84.6)		1885 (83.8)	1557 (86.2)	
yes	112 (9.7)	256 (8.6)		139 (8.8)	137 (9.4)		231 (8.3)	102 (8.3)		221 (9.8)	112 (6.2)	
unknown	60 (5.3)	218 (7.3)		113 (7.2)	99 (6.9)		221 (7.9)	88 (7.1)		143 (6.4)	137 (7.6)	

* P values were calculated using a two-sided Chi-square test.